{"created":"2023-07-25T10:23:09.646800+00:00","id":2780,"links":{},"metadata":{"_buckets":{"deposit":"c01b4cc2-06eb-42a5-bd6d-2e8db1ca8c7e"},"_deposit":{"created_by":3,"id":"2780","owners":[3],"pid":{"revision_id":0,"type":"depid","value":"2780"},"status":"published"},"_oai":{"id":"oai:air.repo.nii.ac.jp:00002780","sets":["611:862:863:1090"]},"author_link":["10234","10229","10235","10228","10232","10230","10238","10239","10237","10226","10240","10241","10231","10233","10227","10236"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-06-30","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"37","bibliographicPageStart":"29","bibliographicVolumeNumber":"43","bibliographic_titles":[{"bibliographic_title":"秋田医学"}]}]},"item_10001_description_5":{"attribute_name":"内容記述（抄録）","attribute_value_mlt":[{"subitem_description":"AIM : To compare the efficacy and safety of triple therapy with simeprevir (SMV) against triple\ntherapy with telaprevir (TPV) while treating chronic hepatitis C (CHC).\nMETHOD : A total of 230 CHC patients were enrolled in the present study. One hundred\nforty-three patients were treated with TPV, and 87 patients were treated with SMV. Univariate\nanalyses were performed to evaluate the pretreatment factors contributing to a sustained virological\nresponse at 24 weeks after the end of treatment (SVR24) and adverse events in the TPV and\nSMV groups.\nRESULT : The SVR24 rates in the TPV and SMV groups were 81.1% and 76.8%, respectively.\nThe difference was not statistically significant. In the TPV group, the rates of anemia, nausea\nand renal dysfunction were significantly higher than those in the SMV group.\nCONCLUSION : In the present study, the SVR24 rates achieved by the two therapies did not\ndiffer to a statistically significant extent. However, the rates of some adverse events in the TPV\ngroup were significantly higher than those in the SMV group. SMV was associated with low risk\nand a high SVR24 rate in patients with HCV.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"秋田医学会"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN00009294","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03866106","subitem_source_identifier_type":"ISSN"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"ARATA, Suguru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHSHIMA, Shigetoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"GOTO, Takashi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"MIURA, Kouichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KOMATSU, Masafumi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKANE, Kunio"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"YAGISAWA, Hitoshi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"TAWARAYA, Hironobu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKAJIMA, Kou"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUNAOKA, Masato"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"HOSHINO, Takao"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"KURAMITSU, Tomoyuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"FUJISHIMA, Yuukou"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"WATANABE, Daisuke"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"AJIMINE, Takuma"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"OHNISHI, Hirohide"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2017-02-16"}],"displaytype":"detail","filename":"akitai43-1(29).pdf","filesize":[{"value":"839.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"akitai43-1(29).pdf","url":"https://air.repo.nii.ac.jp/record/2780/files/akitai43-1(29).pdf"},"version_id":"2ee38b45-88f8-4a3b-b477-324e552a3a4a"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"hepatitis C virus","subitem_subject_scheme":"Other"},{"subitem_subject":"interferon","subitem_subject_scheme":"Other"},{"subitem_subject":"ribavirin","subitem_subject_scheme":"Other"},{"subitem_subject":"telaprevir","subitem_subject_scheme":"Other"},{"subitem_subject":"simeprevir","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR"}]},"item_type_id":"10001","owner":"3","path":["1090"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-08-12"},"publish_date":"2016-08-12","publish_status":"0","recid":"2780","relation_version_is_last":true,"title":["A COMPARISON OF THE EFFICACY AND SAFETY OF TREATMENT WITH SIMEPREVIR AGAINST TELAPREVIR"],"weko_creator_id":"3","weko_shared_id":3},"updated":"2023-07-25T11:32:06.043013+00:00"}